Suzanne Saffie-Siebert

Company: SiSaf Ltd

Job title: Founder & Chief Executive Officer

Seminars:

Separating LNP Manufacture from Cargo Incorporation: The Route to Globally Accessible and Personalised RNA Therapeutics 9:45 am

Understanding the need to introduce RNA payload during LNP formation and the resulting ultra-cold chain requirements limiting the suitability of LNPs for global vaccine rollouts or for small batch production of personalized medicine SiSaf has developed silicon stabilized hybrid LNPs (sshLNPs) that can be produced empty and loaded with RNA cargo in a separate step…Read more

day: Day One